- Oops!Something went wrong.Please try again later.
Investors in CytomX Therapeutic CTMX need to pay close attention to the stock based on moves in the options market lately. That is because the Dec 17, 2021 $7.50 Call had some of the highest implied volatility of all equity options today.
What is Implied Volatility?
Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.
What do the Analysts Think?
Clearly, options traders are pricing in a big move for CytomX Therapeutic shares, but what is the fundamental picture for the company? Currently, CytomX Therapeutic is a Zacks Rank #3 (Hold) in the Medical - Biomedical and Genetics industry that ranks in the Bottom 40% of our Zacks Industry Rank. Over the last 30 days, one analyst has increased the earnings estimate for the current quarter, while one has dropped the estimate. The net effect has widened our Zacks Consensus Estimate for the current quarter from a loss of 16 cents per share to a loss of 18 cents in that period.
Given the way analysts feel about CytomX Therapeutic right now, this huge implied volatility could mean there’s a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
CytomX Therapeutics, Inc. (CTMX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research